Tuesday, 21 March 2023

Business News

Takeda kinase 2 inhibitor meets Phase 2 endpoints in psoriasis patients – TipRanks Financial Blog

Pharvaris initiated with a Buy at Bryan Garnier

Takeda announced “positive results” from a Phase 2b clinical trial of TAK-279, a highly selective, oral allosteric tyrosine kinase 2 inhibitor, in patients with moderate-to-severe plaque psoriasis. The study met its primary and secondary endpoints, with a statistically significant greater proportion of TAK-279 patients achieving Psoriasis Area and Severity Index 75, 90 and 100 in the 5mg, 15mg and 30mg dosing arms compared to placebo at 12 weeks, the company said in a statement. In the Phase 2b study, 259 patients were randomized to receive one of four doses of TAK-279 once-daily, or placebo for 12 weeks.1 Results showed: A significantly greater proportion of TAK-279 patients achieved PASI 75 (44%, 68%, 67%; 5mg, 15mg, 30mg, respectively) versus placebo, meeting the study’s primary endpoint. The frequency of adverse events was 53%-62% in the treatment arms and 44% in the placebo arm. Based on these Phase 2b results, Takeda will initiate a Phase 3 study of TAK-279 in psoriasis in fiscal 2023. Takeda expects topline results from a Phase 2b study in psoriatic arthritis in 2023 and will be evaluating TAK-279 in additional immune-mediated diseases including systemic lupus erythematosus and inflammatory bowel disease.

Published first on TheFly

See Insiders’ Hot Stocks on TipRanks >>

Read More on TAK:

Click Here to Read the Full Original Article at TipRanks Financial Blog…